Compare HAS & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HAS | ABVX |
|---|---|---|
| Founded | 1923 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1B | 9.2B |
| IPO Year | N/A | N/A |
| Metric | HAS | ABVX |
|---|---|---|
| Price | $95.15 | $109.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 11 |
| Target Price | $93.80 | ★ $130.09 |
| AVG Volume (30 Days) | ★ 1.8M | 1.6M |
| Earning Date | 02-10-2026 | 03-23-2026 |
| Dividend Yield | ★ 2.90% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,357,000,000.00 | $6,231,374.00 |
| Revenue This Year | $10.19 | $6.80 |
| Revenue Next Year | $5.44 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 0.79 | N/A |
| 52 Week Low | $49.00 | $4.77 |
| 52 Week High | $97.41 | $148.83 |
| Indicator | HAS | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 70.35 | 39.52 |
| Support Level | $87.90 | $107.42 |
| Resistance Level | $97.41 | $116.72 |
| Average True Range (ATR) | 1.92 | 5.18 |
| MACD | 0.60 | -0.92 |
| Stochastic Oscillator | 81.73 | 13.99 |
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. The firm acquired EOne in 2019, bolting on popular family properties like Peppa Pig and PJ Masks, and since has divested noncore lines from the tie-up. Furthermore, the addition of Dungeons & Dragons Beyond in 2022, offers the firm access to 19 million digital tabletop players.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.